Loading...
Market
Story
FDA Approves Eli Lilly's Zepbound as First and Only Treatment for Sleep Apnea, Reducing Breathing Interruptions by 25
Dec 20, 2024, 09:55 PM
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Zepbound (tirzepatide) as the first and only prescription medication for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This approval, announced on December 20, 2024, allows Zepbound to be used in conjunction with a reduced-calorie diet and increased physical activity. Clinical data indicates that adults using Zepbound experienced at least 25 fewer breathing interruptions per hour, with up to 50% of patients reporting no symptoms after one year of treatment. The approval may also facilitate broader insurance coverage for the medication, which is primarily recognized for its weight-loss benefits.
View original story
Similar markets
Less than 40% • 25%
40% to 50% • 25%
50% to 60% • 25%
More than 60% • 25%
0-25% reduction • 25%
26-50% reduction • 25%
51-75% reduction • 25%
76-100% reduction • 25%
≥ 40% • 25%
30-39% • 25%
20-29% • 25%
< 20% • 25%
≥ 40% • 50%
< 40% • 50%
Improves blood pressure only • 33%
Improves blood pressure and one other measure • 33%
Improves blood pressure and multiple other measures • 33%
≥ 50% • 50%
< 50% • 50%
Less than 60% • 25%
60% to 70% • 25%
70% to 80% • 25%
More than 80% • 25%
Less than 1 million • 25%
1 million to 2 million • 25%
2 million to 3 million • 25%
More than 3 million • 25%
Less than 15% • 25%
15% to 20% • 25%
20% to 25% • 25%
More than 25% • 25%
≥ 10 mmHg • 25%
5-9 mmHg • 25%
1-4 mmHg • 25%
No significant change • 25%
Less than 20% • 25%
20% to 22% • 25%
22% to 25% • 25%
More than 25% • 25%
Less than 20% • 25%
20% to 22% • 25%
22% to 24% • 25%
More than 24% • 25%